By Tessa R. Salazar
Last week, several medical associations expressed their resistance to House Bill No. 4477, or the Compassionate Use of Medical Cannabis Bill authored by Isabela Rep. Rodolfo Albano III. These medical associations declared that the bill ran “contrary to the policy of the state to safeguard the well-being of its citizenry, particularly the youth, from the harmful effects of dangerous drugs,” and that opposing the bill would be part of their “moral and ethical responsibility” to ensure the safety of their patients.
The Food and Drug Administration has approved Genentech’s Avastin for a new use against late-stage cervical cancer, the sixth indication for the blockbuster biotech drug.
A pharmaceutical firm has voluntarily recalled from the market a drug used in organ transplants and the treatment of aplastic anemia.
By Jun Ruiz M.D.
This month the world celebrates Colorectal Cancer Awareness Month. This was first launched in 1999 by the Centers for Disease Control and Prevention in a campaign to promote colon cancer screening. This has been very successful in the United States that colon cancer screening rate among Americans increased from 50 percent in 2002 to 65 percent in 2012.
By Rafael Castillo
A dilemma healthcare professionals like doctors and dentists constantly face is how to balance the beneficial and potentially harmful side effects of all drugs and substances we give our patients. In fact, even placebo or “dummy pills,” which contain no active ingredients, have been shown to have side effects in clinical trials when the patients are “blinded,” or they don’t know whether they’re taking placebo or the active drug.